Opendata, web and dolomites

CAR ART SIGNED

Chimeric Antigen Receptor to generate Alloantigen-specific Regulatory T cells and promote allograft tolerance

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CAR ART project word cloud

Explore the words cloud of the CAR ART project. It provides you a very rough idea of what is the project "CAR ART" about.

prevention    pr    team    immunosuppressive    potency    allograft    vancouver    indicated    france    fellowship    survival    ing    overcome    immune    child    data    graft    cd4foxp3    cancers    transplantation    treatment    transplant    vivo    immunologists    lab    clinically    global    clinical    models    donor    valbonne    ambition    indefinite    alloantigen    ex    relies    successfully    action    car    potent    humoral    rejection    lack    organ    trial    outgoing    supporting    infections    drugs    alloantigens    treg    induction    markedly    specificity    terminal    tenured    generate    family    applicable    recipient    sufficient    mol    regulatory    cells    risk    toward    chimeric    morbidity    therapy    receptor    kidney    tregs    redirect    alloimmune    antigen    de    eacute    clinic    cellulaire    canada    enhanced    human    destructive    pharmacologie    life    performed    group    levings    limitation    grail    researcher    institut    return    glaichenhaus    tolerance    position    hindered    strategies    few    experimental    adoptive    expanded    cellular    culaire    et    transfer    limited    preclinical    translation   

Project "CAR ART" data sheet

The following table provides information about the project.

Coordinator
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 

Organization address
address: RUE MICHEL ANGE 3
city: PARIS
postcode: 75794
website: www.cnrs.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 171˙349 €
 EC max contribution 171˙349 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) coordinator 171˙349.00
2    UNIVERSITY OF BRITISH COLUMBIA CA (VANCOUVER) partner 0.00

Map

 Project objective

Organ transplantation is the best life-supporting treatment for terminal organ failure. Graft survival is however limited by rejection, a destructive process resulting from the response of recipient’s immune system against donor specific alloantigens. Prevention of rejection currently relies on immunosuppressive drugs that lack antigen specificity and therefore increase the risk for infections and cancers. Induction of donor-specific tolerance would provide indefinite graft survival without morbidity and therefore represents the Grail of transplant immunologists. Tolerance has been obtained in experimental models with adoptive transfer of ex vivo-expanded CD4FOXP3 regulatory T cells (Treg). Preclinical studies have indicated that the potency and specificity of Treg therapy could be markedly enhanced by the use of Treg specific for donor alloantigens. Translation of this approach in the clinic has been hindered by the lack of clinically applicable strategies to generate sufficient numbers of potent donor-specific Tregs. To overcome this limitation, Pr Levings’ group (Child and Family Research Institute, Vancouver, Canada) has just recently successfully used chimeric antigen receptor (CAR) technology to redirect the specificity of human Treg toward a transplant-relevant antigen. The objective of the 2-year action is to assess the impact of alloantigen-specific CAR Treg on cellular and humoral alloimmune responses and their ability to promote allograft tolerance. The outgoing phase of the global fellowship will be performed in Pr Levings’ lab, and the return phase in Pr Glaichenhaus’ team (Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France) where the researcher will get in few years a tenured position. The main ambition of the program is to provide key data for the development of a clinical trial with CAR Tregs in kidney transplantation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAR ART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAR ART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

RAMBEA (2019)

Realistic Assessment of Historical Masonry Bridges under Extreme Environmental Actions

Read More  

PROSPER (2019)

Politics of Rulemaking, Orchestration of Standards, and Private Economic Regulations

Read More  

IRF4 Degradation (2019)

Using a novel protein degradation approach to uncover IRF4-regulated genes in plasma cells

Read More